Nationally renowned dermatologist will lead advanced product development & innovation
Mississauga, ON (December 21, 2020) – MedX Health Corporation ("MedX" or the "Company") (TSX-V: MDX), is pleased to announce the appointment of Dr. Trevor Champagne as Chair of the company's Medical Advisory Board. A member of the Advisory Board since 2018—among other distinguished members and world-class dermatologists Dr. Daniel Siegel, Dr. Per Hall, Dr. Joe Walls, and Dr. Dennis Reich—Dr. Champagne has helped position MedX as a leader in teledermatology.
Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care—patient assessment and diagnosis—at a distance, eliminating the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes. Dr. Champagne will drive ongoing innovation with MedX's teledermatology offering, including MedX's leading-edge image capture technology (SIAscopy®) for moles, lesions and other skin conditions via its secure, cloud-based patient management system (DermSecure®), which transmits and stores patient data through the assessment process. MedX's SIAscopy® is the only technology that takes five images, including four spectrophotometric images 2 mm below the skin's surface.
In addition to his leadership appointment at MedX, Dr. Champagne is a dermatologist at the Women's College Hospital in Toronto, as well as an Assistant Professor (Clinician in Quality and Innovation, Division of Dermatology) at the University of Toronto's Temerty Faculty of Medicine, Canada's top-ranked medical school.
"In dermatology, it's critical to have the diagnostic equipment required to provide quick, reliable results for patients in a pain-free way – and MedX delivers this like no other, thanks to their rigorous standards for safety and quality," said Dr. Trevor Champagne. "MedX is a leader in teledermatology because they listen to the dermatology community to develop effective, forward-thinking tools and software that we as specialists, and our patients, need most. I'm honoured to be appointed Chair and look forward to working together with this well-respected team to take teledermatology to the next level."
With both a Doctor of Medicine degree from Western University and a Master of Science, Health Systems Research from the University of Toronto, Dr. Champagne's expertise spans dermatology and computer science. He has been particularly instrumental in the development of DermSecure®, MedX's Patient Management Software, ensuring that it interacts efficiently and effectively with a dermatologist's workflow. He is also overseeing exciting new developments in Artificial Intelligence (AI) functionality, an area of rapid growth, which he will continue to guide in the years to come.
"We're very proud to have a leader of Dr. Champagne's calibre as the first Chair of our Medical Advisory Board," said Mike Druhan, President, Dermatology Services and Products. "His continued leadership and foresight will ensure we are in lockstep with the needs of the dermatology community: not only improving patient care and outcomes today but anticipating and meeting future needs. We are all driven to save lives."
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software than creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA, and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Investor Relations Contact: